Entera Bio set terms for its planned initial public offering on Friday, saying in a regulatory filing it will offer 5 million shares priced at $10 to $12 each. The clinical-stage biopharmaceutical company, which focuses on the development of orally delivered large molecule therapeutics for use in orphan indications and other areas with significant unmet medical needs, will raise $55 million at the midpoint of its price range. It has applied to list on Nasdaq under the ticker symbol “ENTX”. Oppenheimer is sole underwriter on the deal, according to the company’s prospectus.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News